IndiGlobal Labs

What IndiGlobal Labs does

IndiGlobal Labs (Indiglobal Labs Pvt. Ltd.) is a Hyderabad-headquartered Contract Research and Testing Organization founded in 2021, operating from a Cherlapally IDA facility that integrates three service lines: clinical research, bioanalytical methods, and clinical diagnostics. The clinical research practice delivers end-to-end BA/BE study execution for pharmaceutical clients, including protocol development, clinical conduct, biostatistics, data management, and regulatory submission support (including e-CTD report preparation) targeting ANDA filings with global regulators such as USFDA, EMEA, WHO, MHRA, ANVISA, France, Germany, MCC, and NPRA-Malaysia. The bioanalytical methods practice develops and validates LC-MS/MS-based assays for drug quantification across plasma, serum, urine, and saliva matrices, with validated methods covering over 35 molecules including complex combination drugs running on 21 CFR Part 11 compliant systems. The clinical diagnostics practice offers routine and specialized testing (clinical biochemistry, hematology, immunology, molecular pathology including PCR, microbiology, histopathology, COVID-19 testing, and allergy profiling) for patients and healthcare providers, supported by automated analyzers and home sample collection.

The business model is B2B enterprise services sold to pharmaceutical companies for BA/BE and bioanalytical work on a quote-based, project-by-project basis, paired with B2C per-test pricing for diagnostics, distributed via direct sales ([email protected]), the corporate website, and a home sample collection line. The company is DCGI-approved (Aug 2022), DMHO Telangana-approved (Jul 2022), ISO 9001:2015 certified (Apr 2023), NABL 128 accredited (May 2023), and ISP Chile recognized (Dec 2024), giving it multi-jurisdictional regulatory reach from a 52-bed clinical facility (including 2-bed ICU) operated with 51-100 employees. The company is privately held with no disclosed institutional investors, parent company, or acquisitions.

Name

IndiGlobal Labs

Legal name

Indiglobal Labs Pvt. Ltd.

Website

https://indigloballabs.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

51–100 employees

Short description

IndiGlobal Labs is a Hyderabad-based Contract Research and Testing Organization operating a DCGI-approved 52-bed facility, providing clinical research, LC-MS/MS bioanalytical, and clinical diagnostics services to pharmaceutical companies and patients.

Ownership category

akta.pro rank

Product category

Contract Research Organization (Pharmaceutical Clinical Research & Bioanalytical Services)

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Testing Laboratories and Services (541380)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)

akta.pro primary industry

Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG)

akta.pro secondary industries

Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA), Clinical Trial Pharmacy & IMP Management at Site (HLAGACAK), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Contract research organization
• Bioequivalence studies
• Bioanalytical services
• Clinical diagnostics
• Pharmaceutical testing

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Research Services (BA/BE Studies): Contract research services for pharmaceutical companies including protocol development, clinical phase execution (BA/BE studies), bioanalytical analysis, biostatistics, and regulatory submissions. Revenue generated through project-based contracts for generic drug ANDA support.
2. Clinical Diagnostics Services: Diagnostic testing services for patients including clinical biochemistry, hematology, immunology, molecular pathology, microbiology, and histopathology. Revenue generated through individual test pricing and service agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

IndiGlobal Labs is a Contract Research and Testing Organization that sells clinical research, bioanalytical, and diagnostic services. Its Clinical Research Services line conducts DCGI-approved Bioavailability/Bioequivalence (BA/BE) studies and Phase I-IV clinical trial support for pharmaceutical companies, including protocol development, clinical conduct, biostatistics, and e-CTD regulatory submissions. Its Bioanalytical Methods line develops and validates LC-MS/MS-based assays for drugs in biological matrices, and its Clinical Diagnostics line provides pathology, biochemistry, immunology, microbiology, and molecular PCR testing for patients and healthcare providers.

Product overview

IndiGlobal Labs operates as a Contract Research and Testing Organization (CRO) offering an integrated portfolio of three interconnected service lines: Clinical Research Services for protocol development and BA/BE study conduct, Bioanalytical Methods Services for LC-MS/MS-based sample analysis, and Clinical Diagnostics Services for patient disease diagnostics. The company serves pharmaceutical companies requiring regulatory-grade clinical trial support alongside individual patients seeking diagnostic testing, with infrastructure including 52 clinical beds, LC-MS/MS equipment, and automated laboratory analyzers.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Research Services Full-service clinical research offering for pharmaceutical clients including protocol development, BA/BE clinical phase studies, pharmacokinetic studies, biostatistics, data management, clinical trial support, quality assurance, regulatory submissions, and e-CTD report preparation. Targeted at generic and innovative pharmaceutical companies requiring DCGI-approved BA/BE studies to support ANDA and global submissions.
• Bioanalytical Methods Services Bioanalytical method development and validation using LC-MS/MS technology for analysis of drugs in biological matrices including plasma, serum, urine, and saliva. Supports drug development and BA/BE studies for pharmaceutical sponsors, with validated methods for over 35 molecules including complex combination drugs and 21 CFR Part 11 compliant data systems.
• Clinical Diagnostics Services Comprehensive diagnostic testing service for patients and healthcare providers including clinical biochemistry, immuno-hematology, clinical pathology, histopathology, cytopathology, clinical microbiology, molecular pathology (PCR for Hepatitis B, Tuberculosis, Brucella, genetic mutations), COVID-19 testing, and allergy profiling. Includes home sample collection service and online appointment booking.

Quantifiable outcome

• Turnaround time of 3 days for protocol development
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• IQVIA: World's largest CRO with full-service clinical development and laboratory services; competes for the same global pharma BA/BE and bioanalytical RFPs though at vastly greater scale.
• Aurigene Pharmaceutical Services: India-based CDMO/CRO with broader formulation development and manufacturing capabilities overlapping IndiGlobal's clinical and bioanalytical offerings for pharmaceutical sponsors.
• Dr. Lal PathLabs: Pan-India diagnostic chain with NABL-accredited lab network — directly comparable to IndiGlobal's clinical diagnostics arm for patient testing volume and home collection.
• Charles River Laboratories: Global non-clinical and clinical lab services giant that operates early-phase clinical and bioanalytical capabilities serving the same ANDA/BLA sponsor base.

Direct peers

• Synapse Labs: Indian BA/BE-focused CRO with LC-MS/MS bioanalytical capabilities and central lab services; competes head-to-head for ANDA-support contracts and shares founder lineage with IndiGlobal's executive.
• VIMTA Labs: Hyderabad-headquartered CRO offering BA/BE clinical studies, bioanalytical services, and clinical diagnostics — virtually identical service mix to IndiGlobal and the company where IndiGlobal's founders began their careers.
• Accutest Bioresearch (Eurofins): Ahmedabad-based bioanalytical and clinical laboratory now part of Eurofins; competes with IndiGlobal's bioanalytical arm for the same LC-MS/MS-based BA/BE sample analysis work.
• Cliantha Research: Indian CRO offering clinical research, BA/BE, bioanalytical, and dermatology services — overlapping service stack and customer base focused on ANDA and biosimilar programs.
• Veeda Clinical Research: Indian CRO specializing in BA/BE and Phase I studies with in-house bioanalytical capabilities; comparable service portfolio targeting generic-drug sponsors globally.
• Lambda Therapeutic Research: One of India's largest independent CROs running Phase I–IV BA/BE studies, bioanalytics, and clinical trials — directly competes for the same pharma client base at meaningfully larger scale.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/indiglobal_Labs
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/indigloballabs

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IndiGlobal Labs